[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.92.239. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News and Perspectives
June 5, 2013

Zolpidem-Related Surge in Emergency Department Visits

JAMA. 2013;309(21):2203. doi:10.1001/jama.2013.6289

Emergency department visits involving adverse reactions to the sleep medication zolpidem increased 220% from 2005 to 2010, from 6111 visits to 19 487 visits, said the authors of a report issued May 1 by the Substance Abuse and Mental Health Services Administration (SAMHSA). Nearly 3 in 4 zolpidem-related emergency department visits involved patients aged 45 years or older, and roughly two-thirds were women.

An estimated 50 million to 70 million people in the United States have chronic sleep disorders. Zolpidem, a sedative-hypnotic medicine, was approved by the Food and Drug Administration (FDA) in 1992 for the short-term treatment of insomnia and is the active ingredient in such drugs as Ambien, Ambien CR, Edluar, and Zolpimist.

First Page Preview View Large
First page PDF preview
First page PDF preview
×